EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report

Hamza Khoudari, Abdalla Shoaib, Muhammad Nashatizadeh, Nausheen Ahmed, Forat Lutfi, Muhammad Mushtaq, Leyla Shune, Anurag Singh, Sunil Abhyankar, Joseph McGuirk, Haitham Abdelhakim

Leukemia Research Reports · 2026 · 25 · 100577

DOI: 10.1016/j.lrr.2026.100577 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Leukemia Research Reports, 2026. Verfasst von Hamza Khoudari und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Debrecen, Debrecen, Hungary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-BCMA CAR T-cell therapy, specifically ciltacabtagene autoleucel, has significantly improved outcomes for relapsed/refractory multiple myeloma (RRMM). While early-onset immune-effector cell-associated neurotoxicity syndrome (ICANS) is a recognized complication, delayed-onset and non-ICANS neurological syndromes, such as movement and neurocognitive toxicity (MNT), present unique diagnostic and therapeutic challenges. We report a case of a 61-year-old female with a 15-year history of RRMM who developed severe, delayed neurotoxicity 50 days after ciltacabtagene autoleucel infusion. The clinical course began with confusion and rapidly progressed to grade 4 ICANS characterized by lethargy, rigidity, and parkinsonian features. Serial MRI imaging revealed evolving, symmetric T2/FLAIR hyperintensities in the basal ganglia and brainstem, and reactive pachymeningitis. Despite aggressive multi modal immunosuppression, the patient's condition remained refractory and expired on day 93. Post-mortem autopsy confirmed severe bilateral hippocampal sclerosis, diffuse gliosis, and microglial infiltration. This case highlights a fatal presentation of delayed neurotoxicity that overlaps with the emerging MNT phenotype. As CAR-T therapies expand, this case underscores the necessity for prolonged clinical vigilance and the urgent need for novel management strategies for refractory, late-onset neurotoxicity.

Schlagwörter

Stichwörter der Autor:innen

B-cell malignancyCAR-TICANSImmunotherapyMultiple myeloma

Autor:innen und Institutionen

  • University of Debrecen, Debrecen, Hungary.
  • Division of hematologic Malignancies and Cellular therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, Wyandotte.
  • Department of neurology, University of Kansas Medical Center, Kansas City, KS 66160, Wyandotte.

Zitieren

APA

Khoudari, H., Shoaib, A., Nashatizadeh, M., Ahmed, N., Lutfi, F., Mushtaq, M., Shune, L., Singh, A., Abhyankar, S., McGuirk, J., & Abdelhakim, H. (2026). Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report. Leukemia Research Reports, 25, 100577. https://doi.org/10.1016/j.lrr.2026.100577

Vancouver

Khoudari H, Shoaib A, Nashatizadeh M, Ahmed N, Lutfi F, Mushtaq M, et al. Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report. Leukemia Research Reports. 2026;25:100577. doi:10.1016/j.lrr.2026.100577

BibTeX
@article{Khoudari2026,
  author = {Khoudari, Hamza and Shoaib, Abdalla and Nashatizadeh, Muhammad and Ahmed, Nausheen and Lutfi, Forat and Mushtaq, Muhammad and Shune, Leyla and Singh, Anurag and Abhyankar, Sunil and McGuirk, Joseph and Abdelhakim, Haitham},
  title = {Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report},
  journal = {Leukemia Research Reports},
  year = {2026},
  volume = {25},
  pages = {100577},
  doi = {10.1016/j.lrr.2026.100577}
}
Kostenlos starten →